RT Journal Article
SR Electronic
T1 Positive outcomes of 900 mg daily erdosteine in acute exacerbation of COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3393
VO 42
IS Suppl 57
A1 Maurizio Moretti
A1 Andrea Montagna
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3393.abstract
AB Exacerbation of COPD (AECOPD) is characterized by increased production of reactive oxygen species. Aside from its action as a mucolytic, erdosteine is an antioxidant, has anti-inflammatory actions and enhances the activity of antibiotics.AimThe present study investigated whether erdosteine during AECOPD might hasten recovery from the exacerbation.Methods25 COPD patients admitted to hospital with AECOPD, were randomised to 10 day treatment with erdosteine (E) 300 mg tid. (n=13) or matching placebo (P) (n=12), in combination with standard treatment. Serum C-reactive protein (CRP), breathlessness, cough, and sputum scale (BCSS) and pulmonary function tests were measured at hospital admission, at 10 and 30 days post-exacerbation. AECOPD after hospital discharge were assessed at 30 and 60 days.ResultsAt Day 10, CRP was significantly lower in the (E) group. FEV1%pred and BCSS also improved significantly in (E) compared to (P). At Day 30 CRP, pulmonary function and BCSS progressively recovered in both groups. Exacerbation recurrence at 60 days was significantly lower (p<0.05) in the (E) group and positively correlated to serum CRP, marker of systemic inflammation, at 10d (p<0.05) and 30d (p<0.05).View this table:ConclusionsAddition 900 mg daily of erdosteine to concurrent standard treatment modifies the outcome in AECOPD. Antioxidant activity of erdosteine seems to accelerate recovery from AECOPD by reducing the burst of airway inflammation.